Menstrual blood-derived stem cells for the treatment of human pancreatic carcinoma

Abstract

A method and compound product are created from menstrual blood-derived mesenchymal stem cells (MenSCs) with an anti-tumor effect. In particular, the method and compound show the potential anti-tumor effect MenSCs can have on human pancreatic carcinoma, which has been analyzed on the Mia PaCa 2 human pancreatic carcinoma cell line (ATCC #CRL 1420). MenSCs have been proven to have an in vitro anti-tumor effect both in bi-dimensional cultures (monolayer) and in three-dimensional cultures (tumorspheres). Additionally, MenSCs slow down the appearance of pancreatic tumors when they are co-implanted with the pancreatic carcinoma cell line. MenSCs also have an in vivo therapeutic advantage in the treatment of human pancreatic carcinoma via intra-tumor injections.

1 .- 9 . (canceled) 
     
     
         10 . A method of treatment of pancreatic cancer which comprising: administering a pharmaceutical composition comprising menstrual blood-derived stem cells (MenSCs). 
     
     
         11 . The method according to  claim 11 , wherein the pharmaceutical composition comprises MenSC stem cells and a pharmaceutically acceptable vehicle. 
     
     
         12 . A method of treatment of pancreatic cancer comprising: administering a pharmaceutical composition comprising a MenSC conditioned medium. 
     
     
         13 . The method according to  claim 12 , wherein the MenSC conditioned medium is obtained by centrifuging the MenSc culture and only discarding the cells. 
     
     
         14 . The method according to  claim 12 , wherein the MenSC conditioned medium is concentrated or lyophilized. 
     
     
         15 . The method according to  claim 10 , wherein a number of MenSCs is within a ratio between 10:1 to 1:1 of cancer cells: MSCs. 
     
     
         16 . The method according to  claim 10 , wherein cancer cells in relation to MenSC cells administered have a ratio of 10×106 cells: 5×106 cells.